581
Participants
Start Date
July 31, 2012
Primary Completion Date
October 31, 2013
Study Completion Date
October 31, 2013
GSK573719/VI 62.5/25
Inhalation via Novel Dry Powder Inhaler Once a day
GSK573719/VI 125/25
Inhalation via Novel Dry Powder Inhaler Once a day
Placebo
Inhalation via Novel Dry Powder Inhaler Once a day
GSK Investigational Site, Taipei
GSK Investigational Site, Tau-Yuan County
GSK Investigational Site, Taichung
GSK Investigational Site, Changhua
GSK Investigational Site, Kaohsiung Hsien
GSK Investigational Site, Quezon City
GSK Investigational Site, Quezon City
GSK Investigational Site, Jaro, Iloilo City
GSK Investigational Site, Bangkok
GSK Investigational Site, Keelung
GSK Investigational Site, Khon Kaen
GSK Investigational Site, Taichung
GSK Investigational Site, Taichung
GSK Investigational Site, Nan
GSK Investigational Site, Beijing
GSK Investigational Site, Beijing
GSK Investigational Site, Shenyang
GSK Investigational Site, Shenyang
GSK Investigational Site, Shenyang
GSK Investigational Site, Changchun
GSK Investigational Site, Gangdong-gu, Seoul
GSK Investigational Site, Shanghai
GSK Investigational Site, Wuxi
GSK Investigational Site, Qingdao
GSK Investigational Site, Nanchang
GSK Investigational Site, Chongqing
GSK Investigational Site, Chongqing
GSK Investigational Site, Chongqing
GSK Investigational Site, Changsha
GSK Investigational Site, Changsha
GSK Investigational Site, Gaungzhou
GSK Investigational Site, Guangzhou
GSK Investigational Site, Zhanjiang
GSK Investigational Site, Nanning
GSK Investigational Site, Chengdu
GSK Investigational Site, Xi'an
GSK Investigational Site, Xi'an
GSK Investigational Site, Taiyuan
GSK Investigational Site, Chongqing
GSK Investigational Site, Taipei
GSK Investigational Site, Gyeonggi-do
GSK Investigational Site, Gyeonggi-do
GSK Investigational Site, Jeonju
GSK Investigational Site, Seoul
Lead Sponsor
GlaxoSmithKline
INDUSTRY